The Information : Nvidia, Microsoft, Amazon in Talks to Invest Up to $60 Billion

Nvidia, Microsoft, Amazon in Talks to Invest Up to $60 Billion in OpenAI

The Takeaway
  • Nvidia, Amazon, Microsoft are in talks to invest up to $60 billion in OpenAI
  • Investment from Amazon could depend on separate cloud, ChatGPT deals
  • Funding would widen gap with rival Anthropic

OpenAI is lining up huge checks from some of its biggest tech partners, as it seeks to raise up to $100 billion to fund growing demand for its AI. Nvidia, an existing investor whose chips power OpenAI’s AI models, is in talks to invest up to $30 billion, according to a person with knowledge of the situation.

Microsoft, a longstanding backer with exclusive rights to sell OpenAI models to cloud customers, is in talks to invest less than $10 billion. And Amazon, which would be a new investor, is also in talks to invest significantly more than $10 billion, potentially even more than $20 billion.

These investments would be in addition to existing investor SoftBank, which is also in talks to invest up to $30 billion, said two people with knowledge of the situation.

If this extraordinary funding round comes together, it would calm investors worried about the company’s cash burn. Public market investors have lately grown skeptical about OpenAI’s ability to fulfill its spending commitments to Oracle and Microsoft.

The new round could value the company at $730 billion before the financing.

The involvement by the tech giants would give OpenAI vastly more resources to pay to run and train its AI models as well as spend on other compute costs, which it estimated last summer could amount to more than$430 billion between 2026 and 2030, burning nearly $70 billion in the process. It would also significantly widen the funding gap with Anthropic, which has projected its revenue could surpass OpenAI’s in 2029.

It’s not clear which investor will pour the most money in OpenAI’s latest round.

OpenAI is close to receiving term sheets, or an investment commitment from these firms, according to the people. The round is not finalized and institutional investors besides SoftBank are also likely to eventually participate, said one of the people.

The amount that Amazon invests could depend on separate deals the two companies are negotiating, including potentially an expansion of OpenAI’s cloud server rental deal with Amazon, as well as a commercial deal for OpenAI to sell its products, such as enterprise ChatGPT subscriptions, to Amazon.

OpenAI in November said it would spend $38 billion renting servers from AWS over the next seven years, making AWS one of at least five cloud providers OpenAI uses to develop its AI.

Nvidia last fall committed to investing up to $100 billion in OpenAI, which would be spread over multiple years over tranches of $10 billion, as OpenAI deploys gigawatts of chips. However, that deal is still not finalized and would be separate from Nvidia’s discussions to invest in OpenAI’s current round, said one of the people.

TheRealDeal : CoStar activist investor seeks to overhaul “feckless board,” cut l

CoStar activist investor seeks to overhaul “feckless board,” cut losses in Homes.com
Hedge fund Third Point criticized CoStar CEO Andy Florance in letter to board

Less than a year after securing board changes at CoStar Group, hedge fund Third Point is back with another ultimatum: replace most of the board, rein in executive pay and find an exit from Homes.com.

Third Point plans to nominate several directors to CoStar’s eight-person board as part of an effort to reverse the company’s push into the residential real estate space through its investment in Homes.com, according to a letter to the board from Third Point CEO Daniel Loeb made public on Tuesday.

In addition to replacing the majority of the current board, Loeb called for executive compensation to be tied more closely to performance and for CoStar to find an exit strategy for Homes.com and its other residential enterprises.

CoStar, which is considered the market leader in commercial real estate data, began its push into residential real estate around five years ago, when it purchased Homes.com. Loeb estimated that CoStar has spent roughly $5 billion investing in its residential real estate, with an expected revenue of $80 million for 2025.

The letter comes less than a year after Third Point and hedge fund D.E. Shaw initially raised concerns over the direction of the company, leading to the appointment of three new members to the board, an independent board chair and the establishment of a capital allocation committee to review CoStar’s investment in Homes.com and its timeline for profitability.

Earlier this month, CoStar announced that it would significantly scale back its investment in Homes.com in an effort to reach profitability by 2030.

Those efforts have not been enough for Loeb, who excoriated the company’s strategic direction and singled out CoStar CEO Andy Florance for compensation he says is out of step with his performance.

“The Company’s anemic performance can be ascribed entirely to the misallocation of billions of dollars into Homes.com, overseen by a feckless board of directors that has failed to protect shareholders from Mr. Florance’s quixotic quest while rewarding him with exorbitant pay packages,” Loeb wrote.

Loeb pointed to CoStar’s stock price, which has fallen 27 percent over the past five years while the S&P 500 has nearly doubled in that time, as evidence of the company’s failure. CoStar’s stock price jumped over 5 percent to $69.53 at the market open on Tuesday.

Loeb also criticized Florance’s compensation, which he said was $37 million in 2024. That puts Florance in the top decile of of S&P 500 CEOs based on compensation, according to the letter.

Loeb also criticized the company’s repeatedly revised projections, pointing to guidance provided four years ago towards $700 million in revenue by 2027, which was later abandoned. He wrote that he believes the company’s core commercial business is made up of “a collection of exceedingly strong franchises” that he sees achieving long-term profitability.

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Applied Materials (AMAT) upgraded to Outperform from Neutral at Mizuho, tgt $370
    • Bank of Montreal (BMO) upgraded to Buy from Hold at TD Securities
    • Circle Internet Group (CRCL) upgraded to Neutral from Underperform at Mizuho, tgt $77
    • Energy Fuels (UUUU) upgraded to Neutral from Sell at Roth Capital, tgt $15.50
    • Johnson & Johnson (JNJ) upgraded to Overweight from Equal Weight at Morgan Stanley, tgt $262
    • KKR (KKR) upgraded to Buy from Hold at HSBC, tgt $144
    • Korro Bio (KRRO) upgraded to Overweight from Neutral at Cantor Fitzgerald, tgt $21
    • Microchip (MCHP) upgraded to Buy from Neutral at BofA Securities, tgt $95
    • Nextpower (NXT) upgraded to Overweight from Sector Weight at KeyBanc, tgt $142
    • Texas Instruments (TXN) upgraded to Neutral from Underperform at BofA Securities, tgt $235
    • Visa (V) upgraded to Buy from Neutral at Rothschild & Co Redburn, tgt $385
  • Downgrades:
    • Array Technologies (ARRY) downgraded to Neutral from Outperform at Robert W. Baird, tgt $11
    • Banco Bilbao Vizcaya Argentaria (BBVA) downgraded to Sector Perform from Outperform at RBC Capital
    • BJ's Wholesale (BJ) downgraded to Hold from Buy at Jefferies, tgt $90
    • Brown & Brown (BRO) downgraded to Neutral from Buy at Citigroup, tgt $83
    • Capital City Bank Group (CCBG) downgraded to Market Perform from Outperform at Keefe Bruyette, tgt $45
    • Coca-Cola Femsa (KOF) downgraded to Neutral from Overweight at JPMorgan, tgt $100
    • Martin Marietta Materials (MLM) downgraded to Hold from Buy at Loop Capital, tgt $690
    • Nucor (NUE) downgraded to Neutral from Buy at UBS, tgt $183
    • PayPal (PYPL) downgraded to Sell from Neutral at Rothschild & Co Redburn, tgt $50
    • Plains All American Pipeline (PAA) downgraded to Underperform from Neutral at BofA Securities, tgt $19
    • Plains GP Holdings (PAGP) downgraded to Underperform from Neutral at BofA Securities, tgt $19
    • Portfolio Recovery Associates (PRAA) downgraded to Market Perform from Outperform at Citizens
    • Rio Tinto (RIO) downgraded to Equal Weight from Overweight at Morgan Stanley
    • Roper Technologies (ROP) downgraded to Hold from Buy at Stifel, tgt $385
    • Roper Technologies (ROP) downgraded to Perform from Outperform at Oppenheimer
    • Western Alliance Bancorporation (WAL) downgraded to Neutral from Overweight at JPMorgan, tgt $105
  • Others:
    • 4D Molecular Therapeutics (FDMT) assumed with an Overweight at Barclays, tgt $33
    • Aardvark Therapeutics (AARD) initiated with a Buy at B. Riley, tgt $32
    • Alnylam Pharmaceuticals (ALNY) assumed with an Overweight at Barclays, tgt $527
    • Altimmune (ALT) initiated with an Overweight at Barclays, tgt $20
    • Apellis Pharmaceuticals (APLS) initiated with an Equal Weight at Barclays, tgt $24
    • Ascendis Pharma (ASND) initiated with an Overweight at Barclays, tgt $342
    • BioMarin Pharmaceutical (BMRN) assumed with an Overweight at Barclays, tgt $80
    • BridgeBio Pharma (BBIO) initiated with an Overweight at Barclays, tgt $157
    • Celestica (CLS) initiated with a Buy at BofA Securities, tgt $400
    • Coinbase Global (COIN) initiated with a Neutral at Robert W. Baird, tgt $240
    • Cytokinetics (CYTK) assumed with an Overweight at Barclays, tgt $87
    • FormFactor (FORM) initiated with a Hold at Freedom Capital, tgt $64
    • Gossamer Bio (GOSS) initiated with an Overweight at Barclays, tgt $9
    • HeartFlow (HTFL) initiated with an Overweight at Wells Fargo, tgt $38
    • Insmed (INSM) initiated with an Overweight at Barclays, tgt $231
    • Ionis Pharmaceuticals (IONS) assumed with an Overweight at Barclays, tgt $95
    • Inventiva (IVA) initiated with an Overweight at Barclays, tgt $18
    • Kymera Therapeutics (KYMR) assumed with an Overweight at Barclays, tgt $133
    • Madrigal Pharmaceuticals (MDGL) initiated with an Overweight at Barclays, tgt $964
    • MBX Biosciences (MBX) initiated with an Overweight at Barclays, tgt $66
    • Moderna (MRNA) assumed with an Equal Weight at Barclays, tgt $25
    • Nano Nuclear Energy (NNE) initiated with a Buy at Texas Capital, tgt $49
    • NuScale Power (SMR) initiated with a Buy at Texas Capital, tgt $23
    • Oklo (OKLO) initiated with a Buy at Texas Capital, tgt $138
    • PTC Therapeutics (PTCT) assumed with an Overweight at Barclays, tgt $119
    • Raymond James Financial (RJF) initiated with an Overweight at Barclays, tgt $191
    • Regenxbio (RGNX) assumed with an Overweight at Barclays, tgt $37
    • Sagimet Biosciences (SGMT) initiated with an Equal Weight at Barclays, tgt $8
    • Sarepta Therapeutics (SRPT) assumed with an Equal Weight at Barclays, tgt $20
    • Shattuck Labs (STTK) initiated with an Overweight at Piper Sandler, tgt $15
    • TPG (TPG) initiated with an Overweight at Barclays, tgt $78
    • Tyra Biosciences (TYRA) initiated with an Overweight at Barclays, tgt $59
    • uniQure (QURE) initiated with an Equal Weight at Barclays, tgt $31
    • Vertex Pharmaceuticals (VRTX) assumed with an Overweight at Barclays, tgt $606

>>US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • LRN +32.5%, NXT +13.9%, STX +10.3%, FFIV +9.8%, TXN +8.7%, MANH +6.9%, WIX +6.6%, ASML +6.2%, SYBT +3.7%, EDU +3.6%, VFC +3.6%, ALHC +2.9%, BXP +2.9%, LZ +2.8%, DGII +2.8%, PONY +2.7%, BROS +2.5%, RYN +2.3%, APLS +2%, FCF +1.8%, TTMI +1.5%, NGD +1.1%, EMBJ +1.1%, ADM +1.1%, LYFT +1%, ODV +1%, LC +0.9%, ITRI +0.8%, WRD +0.8%, SF +0.7%
  • Gapping down:
    • VENU -19.9%, ALT -15%, TRMK -14.9%, QRVO -11.3%, UMC -9.9%, ELVR -9.8%, SARO -7.8%, PFS -7%, ELV -6.5%, GEF -4.9%, BZAI -3%, DHR -1.6%, PCH -1.4%, SM -0.9%, PKG -0.8%, CCIX -0.7%

>>> Europe : Brokers Upgrades & Downgrades - 28th of January 2026 V3(++)

>>> Up
* Continental PT Raised to 90 euros from 80 euros at UBS (++)
* DiaSorin Raised to Neutral at BNP Paribas (+)
* Engie PT Raised to 27 euros from 25.70 euros at Jefferies
* Getinge Raised to Buy at Pareto Securities; PT 240 kronor
* HMS Networks Raised to Buy at Nordea; PT 500 kronor
* HMS Networks Raised to Buy at Handelsbanken; PT 460 kronor (++)
* Johnson & Johnson Raised to Overweight at Morgan Stanley
* Kemira Raised to Accumulate at OP Corporate Bank; PT 21.50 euros (++)
* KKR & Co. Raised to Buy at HSBC; PT $144
* Partners Group Raised to Buy at Kepler Cheuvreux (++)
* PSP Swiss Raised to Buy at UBS; PT 162 Swiss francs
* Ringkjoebing Landbobank Raised to Hold at ABG; PT 1,575 kroner
* Siegfried Raised to Buy at Octavian; PT 125 Swiss francs
* Swiss Prime Raised to Neutral at UBS; PT 125 Swiss francs
* Tecnotree Raised to Hold at Inderes; PT 5.70 euros
* UPS PT Raised to $115 from $101 at TD Cowen
* Visa Raised to Buy at Rothschild & Co Redburn; PT $385

>>> Down
* 2020 Bulkers Cut to Hold at Fearnley; PT 145 kroner (+)
* Alleima Cut to Hold at DNB Carnegie (++)
* Atlas Copco Cut to Hold at Pareto Securities; PT 200 kronor
* Atlas Copco Cut to Hold at ABG; PT 190 kronor
* BBVA Cut to Sector Perform at RBC; PT 19.75 euros
* BioMerieux Cut to Neutral at BNP Paribas (+)
* Birkenstock PT Cut to $47 from $57 at Morgan Stanley
* BKW Cut to Underperform at ZKB (+)
* Boliden Cut to Hold at Kepler Cheuvreux; PT 640 kronor (++)
* Domino's Pizza PT Cut to $450 from $490 at Guggenheim (++)
* Enel Chile ADRs Cut to Neutral at Grupo Santander; PT $4.60
* Essity Cut to Hold at Pareto Securities; PT 270 kronor
* Evli Cut to Reduce at Inderes; PT 26 euros
* F-Secure Cut to Hold at Danske Bank Markets; PT 2 euros (++)
* H&R Cut to Reduce at Kepler Cheuvreux; PT 4 euros (++)
* Intershop Cut to Neutral at UBS; PT 170 Swiss francs
* LVMH Cut to Neutral at CIC; PT 620 euros (++)
* Mobimo Cut to Sell at UBS; PT 330 Swiss francs
* Neste Cut to Neutral at UBS; PT 23 euros
* PayPal Cut to Sell at Rothschild & Co Redburn; PT $50
* Redeia Cut to Neutral at Citi; PT 15.60 euros
* Roche Cut to Hold at Intron Health; PT 350 Swiss francs
* SocGen Cut to Market Perform at KBW; PT 77 euros
* Solvay Cut to Hold at ING; PT 26 euros
* Teleperformance PT Cut to 55 euros from 92 euros at UBS (++)
* Var Energi Cut to Hold at Norne Securities; PT 39 kroner
* Veidekke Cut to Hold at ABG; PT 185 kroner
* Wacker Chemie Cut to Hold at mwb research AG; PT 75 euros (++)

>>> Initiation
* Blue Cap Rated New Buy at mwb research AG; PT 29 euros (++)
* Coloplast Resumed Market Perform at Bernstein; PT 555 kroner (+)
* Convatec Group PLC Resumed Outperform at Bernstein; PT 295 pence (+)
* CTT Rated New Buy at TP ICAP Midcap; PT 9.40 euros
* Inventiva SACA ADRs Rated New Overweight at Barclays; PT $18
* Nano Nuclear Energy Rated New Buy at Texas Capital; PT $49
* Oklo Rated New Buy at Texas Capital; PT $138
* Philips Rated New Accumulate at KBC Securities; PT 27.50 euros (+)
* Warner Music Rated New Buy at MoffettNathanson LLC; PT $38
* Valbiotis SA Rated New Buy at Euroland Corporate; PT 2.16 euros

>>> Call
* Alstom Hits Four-Year High as JPMorgan Adds to Focus List (++)
* BBVA Best-in-Class But Fully Valued, RBC Cuts to Sector Perform
* Ferragamo Retail Sales Stand Out, Wholesale Drags, JPMorgan Says
* Goldman Strategists: Trade Deal To Lift EU India-Exposed Stocks (++)
* Neste Cut to Neutral at UBS With Improved Outlook Priced in (+)
* PSP Swiss Hits 2020-High as UBS Upgrades ‘Quality Laggard’ (++)
* Redeia Downgraded at Citi, Regulatory Framework is Restrictive
* Roche Risk-Reward Now More Balanced, Intron Health Cuts to Hold

FT : Investment in Europe’s chemicals sector plunges over 80% in 2025 its edge

Investment in Europe’s chemicals sector plunges over 80% in 2025
High energy prices, red tape and Chinese imports impede ability to supply region’s critical industries

Investment in Europe’s chemicals sector fell over 80 per cent in 2025 and plant closures doubled, as industry leaders warned that the continent would become dependent on China for the raw materials needed in its automotive, healthcare and defence industries.

Confirmed investments fell from 1.9 megatonnes of capacity in 2024 to 0.3 megatonnes last year, as the sector struggled with high energy prices, suffocating bureaucracy and an expansion of Chinese imports, according to a report published on Wednesday by the European Chemical Industry Council (Cefic).

The announced plant closures had directly affected about 20,000 jobs across Europe since 2022 and led to 17.2 megatonnes worth of production capacity disappearing last year, double that from 2024 and a sixfold rise from 2022, Cefic said.

“If you want a defence sector . . . an automotive sector, it’s totally dependent on chemicals supplying the materials. This is simply a chokehold the rest of the world has on Europe,” said Marco Mensink, director-general of Cefic.

“We are now 95 per cent dependent on vitamins from China and India,” he added. The chemicals sector was “the mother of all industries and it’s breaking down as we speak”, he warned.

Over the past four years, businesses across Europe have said they will shutter plants making chemicals ranging from the chlorine needed to treat drinking water to the phenols used in printed circuit boards and paracetamol. The closures have led to the loss of about 9 per cent of Europe’s chemical production capacity, according to Cefic.

Investors have scaled back plans to invest on the continent or pulled out entirely, having been hit by onerous carbon taxes and cheap imports from China.

Industry leaders, including Ineos’s Sir Jim Ratcliffe, have warned that without action, Europe would be “dependent on China for the core materials that support defence, healthcare, food and manufacturing”. Ineos last year filed 10 anti-dumping cases against imports of cheap chemical products into the EU and closed production facilities in Germany, calling on the bloc for “tariff protection”.

This month, Vioneo, a subsidiary of AP Møller-Maersk, abandoned plans for a green plastics plant in Antwerp, Belgium, in favour of constructing a plant in China that it said was closer to supplies of green methanol and would be cheaper to build.

The chemicals industry was behind a cross-industry statement signed in Antwerp by some 1,300 organisations and businesses in 2024 stressing the “urgent need for clarity, predictability and confidence in Europe and its industrial policy”.

It is planning a third Antwerp summit this year amid fears that not enough has been done to halt the decline of European heavy industry.

Cefic’s Mensink said policymakers in Europe had belatedly begun to face up to the challenges facing the sector but that progress was too slow. “What you see is that the world is changing faster than policymakers catch up at the moment. They need to go from third to fifth gear.”

The European Commission in July presented a policy document laying out actions it would take to support the chemicals sector, including efforts to designate critical chemicals and production sites to help co-ordinate funding, to speed up permitting of industrial sites and improve monitoring of trade flows.

Energy prices, which soared after Russia’s full-scale invasion of Ukraine, make up about 75 per cent of production costs for petrochemicals and remain stubbornly high. Phasing out Russian gas, which the EU aims to ban by 2027, has meant that the bloc has become reliant on global markets for more expensive liquefied natural gas.

Companies are also struggling with the bloc’s ambitious green agenda, which commits EU countries to reach net zero emissions by 2050, but has introduced vast amounts of red tape in pursuit of that goal.

FT : How private equity’s pioneer in tapping retail money lost its edge

How private equity’s pioneer in tapping retail money lost its edge
From Switzerland, Partners Group built a $185bn business by serving individual investors. Bigger US rivals have the market in their sights

Private equity’s most successful advocate for opening up the once-exclusive asset class to the American masses is a firm not headquartered in New York, Washington or indeed in the US at all.

From its base on the outskirts of Zug, 4,100 miles away from the centre of US policymaking, a Swiss investment colossus built a $185bn business by serving wealthy individuals products they could sell in and out of with ease.

Like other private equity firms, Partners Group was hindered by US rules in serving America’s giant retirement market: an untapped source of demand that had the potential to be hugely lucrative, and one that Partners was determined to unlock.

Last August it succeeded, with US President Donald Trump’s executive order to make 401k savings accounts accessible to private equity.

But the firm that pioneered private equity for the people may not be the one to reap the rewards.

The victory came as Partners found itself suffering for the first time net redemptions at its flagship US fund and with new competition from rivals that have set their sights on the marketplace it developed.

Where groups such as Blackstone, Apollo and KKR previously wooed institutions to lock up capital for a decade, the $22tn private capital industry is now switching to a battle for the wealthy individuals and retirement savers that long formed the bedrock of Partners’ business.

“[Partners] invented the wealth market, but where are they really today with all these others launching products?” said one former senior employee.

At Partners’ headquarters, giant Victorian lettering reads “Built differently to build differently” from one of two mock 19th-century warehouses. The site is meant to embody an investing culture that prioritises industrial knowledge over financial engineering — a deliberate contrast with the US private capital powerhouses.

Partners’ heritage is different, to a point. Unlike most buyout groups, established by seasoned dealmakers, Partners was founded 30 years ago by three young Goldman Sachs alumni with backgrounds in sales and private banking.

Marcel Erni, the group’s cerebral founder, focused on investments. Fredy Gantner, a Mormon bishop, was chief executive. The lowest-profile founder, Urs Wietlisbach, led sales.

Their expertise was not in striking deals but in serving clients, something that would be crucial to the firm’s development.

What Partners recognised early was that there was a lack of private equity expertise among Swiss and German investors, presenting a sales opportunity. It made smart use of its Swiss roots, according to industry insiders, forging deep ties with local private banks such as Vontobel that gave the firm a base of potential clients willing to pay lucrative fees.

They were “serving the underdog that no other firm wanted to serve”, one former employee said. While it did some of its own buyouts, Partners primarily invested in others’ funds. “They hated when you called them a fund of funds but that’s effectively what they were,” said a former adviser.

Because Partners lacked a steady pipeline of direct deals to offer clients, it was forced to come up with other structures to fit their needs. “That innovation gene was there out of necessity,” another former worker said.

That led to an innovation that would propel the firm’s success: a new type of fund that packaged private investments in a way that suited individuals and small institutions: the evergreen or “semi-liquid” vehicle.

Partners does cater to traditional private equity investors, both through closed-end funds and separately managed accounts operated for institutions. But in 2003, it became the first large firm to offer buyout investments to mainstream investors.

That was the start of a remarkable run. Within a decade of a US version launching in 2009, Partners had captured more than two-thirds of the American retail market for private markets funds, according to Goldman Sachs, while rivals were focused on making money from prestige clients such as pensions and sovereign wealth funds.

Partners combined its new structure with another innovation: its willingness to tailor its product to suit its clients, rather than adopting the take-it-or-leave-it approach more common to its buyout group peers.

For institutions, the firm’s use of separately managed accounts allowed investors to focus on specific strategies or regions of their choosing. The result is a structure of dizzying complexity, according to advisers, with more than 350 vehicles that can participate in deals allocated by algorithm to give everyone a share of the action.


Partners said this flexibility was core to its appeal, providing each client “equal access” to its deal flow based on a “pro rata allocation policy”. But it is difficult to assess the performance of many of Partners’ funds because the firm does not publish the individual returns of its separately managed accounts.

“They’ve always been prepared to do things a bit differently,” said a former private markets equities analyst. “There was an element of them being a pathfinder.”

In 2006, Partners became one of the first private markets firms to go public. “They felt having a public quotation would give them more credibility,” said one adviser on the initial public offering.

US rivals Blackstone, Apollo and KKR followed suit. While some bosses, such as Blackstone co-founder Stephen Schwarzman, complained about stagnant public market values in the ensuing decade, Partners’ shares soared.

The consistency of its management fee income attracted shareholders in Europe, even as Blackstone and Apollo struggled to win over investors thanks to the unpredictable timing of lucrative deal windfalls. “They weren’t going public as Europe’s KKR,” the adviser said. “The story was primarily that they were a substantial [investor] in all sorts of funds.”

That changed after the IPO. From 2011, the firm started to focus more on originating its own deals, a move that frustrated some buyout groups that found one of their fund investors had turned competitor.

Any such tensions were no longer an issue, Gantner told the FT.

Instead, it is Partners’ US rivals that are increasingly occupying its traditional territory.

As commitments to the sector from big institutional backers have slowed, Blackstone, Apollo and KKR have started to aggressively target individual investors. With new funds and armies of staff, these US rivals have seized market share.

Last year, investors for the first time pulled money overall from Partners’ main private equity fund for wealthy US investors as it underperformed newer offerings from its better-known competitors. Redemptions from the $16.5bn Private Equity Master fund accelerated in 2025, reaching a record of $750mn in the third quarter — roughly double the figure for the same quarter a year earlier.

By November, the Swiss firm’s share of the US market had fallen to less than 25 per cent, according to Goldman.

Partners’ funds risk becoming increasingly unattractive, according to Patrick Dwyer, a US wealth manager, as rivals such as Blackstone have used their larger deal pipelines to create funds for individuals with broader investment offerings and lower overall costs.

While the Swiss group’s stock outperformed its US-listed competitors in its first dozen years as a public company, it has lagged badly over the past five years. In 2018, the Swiss group had a market value roughly equal to Apollo and KKR combined. Now, it is less than a third of the size of either.

“It is an uncompetitive product compared to the newer funds,” Dwyer said of Partners’ flagship evergreen fund structure.

The Swiss firm — whose flagship retail fund in the third quarter underperformed “almost all other evergreen funds we track”, according to Goldman — insists that the fund, which accounts for 9 per cent of its overall assets, remains attractive. It offered investors greater transparency and regulatory standards than newer competitors, Partners said.

The firm’s assets increased by $33bn in 2025, and it has said the nine new evergreen funds launched since 2023 are attracting assets and performing well.

But weak returns at its flagship US and European retail funds have been a drag.

The main US master fund, which soared in value in 2021 and 2022, has returned between 2 and 8 per cent a year after fees in the period since. That is lower than newer offerings from KKR and Blackstone, though the firm believes the comparison is unfair, given that the new crop of funds are investing after a reset in private valuations.

Recent returns have also been below the fund’s own 11 per cent annualised net return since 2009, however. Partners’ “global value” fund for European investors, which has more than $9bn in assets, has also generated tepid annual returns of between 0.3 and 8.3 per cent over the past four years.

The group’s head of portfolio solutions, Roberto Cagnati, said higher reported returns elsewhere in the industry had limited grounding in reality.

“Many of the industry’s newer funds are doubling in size every few quarters, with investments entirely based on book value and no track record of realisations,” he said. “Any fund that launched after 2023 has had the benefit of a markedly different investment environment following the fast rate hikes in 2022.”

“There is a lot of apples-to-oranges comparison going on when people look at private equity evergreen performance today,” Cagnati added.

Partners’ traditional closed-ended funds have performed better. It has had some successful deals at a time when other private equity groups have struggled to exit investments. It last year sold a stake in International Schools Partnership after tripling its value in four years; its 2024 listing of retail brand Vishal Mega Mart returned seven times Partners’ investment, according to a person familiar with the firm.

But the firm admits that, like the wider buyout industry, some of the assets it bought in 2021 and 2022 now look overpriced. A deal for watchmaker Breitling came just before a slowdown in the global market for Swiss watches, while a portfolio company acquired in 2018, Hearthside Food Solutions, collapsed in November 2024 after allegations of child labour.

“[Partners has] very strong guidance on performance fees for this year and 2026 and 27 because they have some old direct investments maturing . . . But . . . what’s next? What’s beyond 27-30?” said one private banker.

In the meantime, Partners must manage redemptions at its flagship evergreen US fund, its single biggest source of fees. Net redemptions at its US fund are running at about $320mn a quarter, or nearly 2 per cent of its net assets.

Together with two evergreen funds favoured by European investors, the three have collectively suffered billions of dollars in net redemptions in recent years after previously recording almost uninterrupted growth.

Partners said it had conservatively managed liquidity, setting aside assets to meet redemptions. It said it had also guarded against growing too quickly by sometimes turning away new assets and sought to keep investors’ expectations for returns in check.

Rekindling growth may hinge on whether the firm can win in the market for US savers that it helped pioneer.

To try to keep its edge, Partners has struck deals with asset managers including BlackRock and PGIM to expand its customer base.

Nicholas Herman, equity analyst at Citi, said that despite the “growing narrative” last year that relatively weaker performance and demand in the firm’s big evergreen funds could cause Partners to fall behind, the firm had been able to successfully strike deals and launch newer strategies in part thanks to its much “longer-term track record”.

Its rivals have similar ideas, however. Blackstone has a partnership with Vanguard, while KKR and US investment giant Capital Group have an exclusive venture. Apollo is building new retail products that promise to “be a reimagination of what private equity is as an industry”.

Partners could also bulk up to help it compete. It has told shareholders it expects to be a buyer as the private capital industry consolidates, and has been searching for a signature deal — or “a brand that is compelling for investors”, as chief executive David Layton told the FT in August.

Discussions with Advent International and Leonard Green came to nothing and Partners has moved on to studying smaller deals that would add closer to $50bn in assets, according to people familiar with the matter. (Advent and Leonard Green declined to comment.)

Layton told the FT it was normal for his firm to be losing some share of the market it invented.

“We were doing the missionary work to create something, and now you have this kind of wave that’s building,” he said. “There’s obviously going to be a lot of new entrants . . . But it’s clear there’s structural growth there and Partners Group has a big role to play.”